TABLE 1.
Characteristics of Patients at Baseline
| Characteristic | All patients (n = 98) | Efficacy cohort | |
|---|---|---|---|
| Surgery cohort (n = 77) | 99mTc-sestamibi cohort (n = 60) | ||
| Median age (y) | 64 (range, 17–90) | 66 (range, 17–86) | 65 (range, 17–85) |
| Sex | |||
| Male | 26 (27) | 18 (23) | 13 (22) |
| Female | 72 (73) | 59 (77) | 47 (78) |
| Prior parathyroidectomy | 41 (42) | 26 (34) | 24 (40) |
| Prior imaging with 99mTc-sestamibi | |||
| Total | 92 (94) | 73 (95) | n/ |
| Within 12 mo | 77 (79) | 62 (81) | n/ |
| Number positive | 44 (57) | 43 (59) | n/ |
| Ultrasound | |||
| Total | 94 (96) | 76 (99) | 59 (98) |
| Number positive | 45 (48) | 41 (54) | 33 (56) |
| Baseline laboratory values (mean ± SD) | |||
| Calcium | 10.6 ± 0.6 | 10.7 ± 0.6 | 10.7 ± 0.5 |
| Parathyroid hormone | 116 ± 119 | 122 ± 132 | 125 ± 143 |
| 18F-fluorocholine–positive for adenoma* | 94 (96) | 75 (97) | 58 (97) |
| Surgical results | |||
| Adenoma found at surgery | NA | 75 (97) | 58 (97) |
| Biochemical cure after surgery | NA | 63 (85)† | 48 (84)† |
*
Positive determined by consensus of masked readers.
†
3 patients had no follow-up laboratory values available for review.
NA = not applicable.
Data are number followed by percentage in parentheses unless otherwise noted.